Kadcyla Reproduces Hopes for Breast Cancer Treatment
According to a new research report by RNCOS entitled, "Global Antibody Drug Conjugate Market Outlook 2018", the rise of Kadcyla represents an entirely new way to treat HER2 positive breast cancer. In one of the Phase III trials, the drug delivered a 32% reduction in death risk in comparison to a standard care of treatment. Even the molecule has doubled the delay in disease progression for advanced breast cancer patients. Roche Genentech Blockbuster ADC poses a revolutionary treatment option for...
View full press release